SAT-LB030 Efficacy of Combined Therapy with Metformin and Sitagliptin in Patients with Type 2 Diabetes Who Did Not Reach Target Levels of Glycated Hemoglobin on Metformin Monotherapy

Background and aims: The purpose of this study was to evaluate the effects of sitagliptin 100 mg in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin ≥1500mg/day. Materials and methods: Outpatients aged 52-72 years with type 2 diabetes. Patients were on metformin monotherapy (>=1500 mg/day) for >=8 weeks with a A1C >=7.5% and <=11.0% before treatment with sitagliptin. Glycemic efficacy endpoints were included the changes from baseline in A1C and FPG at week 26 and also Percentage of Participants Achieving a HbA(1c) of <7%. Other efficacy endpoints that were assessed include changes from baseline at week 26 in body weight, and some safety endpoints such as hepatic safety tests ALT and AST, total and direct bilirubin, renal failure tests - serum creatinite calculated using the CKD-EPI formula, urinary albumin/creatinine ratio. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: Target HbA(1c) (<7%) was achieved in 83.3% overall with no incidence of hypoglycemic episodes ( and some other side-effects (25%-female genital mycotic infection). 26 weeks after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 13.99% ± 0.8% (mean HbA1c before administration was 8.76% ± 0.8%) . Furthermore, sitagliptin was well tolerated in the group. On logistic regression analysis, baseline HbA(1c) was the strongest contributing factor for achieving target HbA(1c); baseline body mass index and duration of diabetes were also significant factors. Conclusion. Sitagliptin as combination therapy with metformin was effective and safe in type 2 diabetes patients. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.